4//SEC Filing
Khuong Chau Quang 4
Accession 0000899243-20-030411
CIK 0001800315other
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 8:00 PM ET
Size
42.9 KB
Accession
0000899243-20-030411
Insider Transaction Report
Form 4
Galecto, Inc.GLTO
Khuong Chau Quang
Director10% Owner
Transactions
- Award
Series D Preferred Stock
2020-09-25$27.11/sh−148,395$4,022,988→ 148,395 total(indirect: See footnote)→ Common Shares (385,782 underlying) - Conversion
Series C-2 Preferred Stock
2020-11-02−116,800→ 0 total(indirect: See footnote)→ Common Shares (303,645 underlying) - Conversion
Series C-5 Preferred Stock
2020-11-02−77,866→ 0 total(indirect: See footnote)→ Common Shares (202,428 underlying) - Conversion
Series D Preferred Stock
2020-11-02−148,395→ 0 total(indirect: See footnote)→ Common Shares (385,782 underlying) - Conversion
Common Shares
2020-11-02+2,055,824→ 2,055,824 total(indirect: See footnote) - Conversion
Common Shares
2020-11-02+191,787→ 191,787 total(indirect: See footnote) - Award
Series D Preferred Stock
2020-09-25$27.11/sh−59,350$1,608,979→ 59,350 total(indirect: See footnote)→ Common Shares (154,292 underlying) - Conversion
Series C-4 Preferred Stock
2020-11-02−109,013→ 0 total(indirect: See footnote)→ Common Shares (283,402 underlying) - Conversion
Series C-5 Preferred Stock
2020-11-02−31,147→ 0 total(indirect: See footnote)→ Common Shares (80,972 underlying) - Conversion
Series D Preferred Stock
2020-11-02−59,350→ 0 total(indirect: See footnote)→ Common Shares (154,292 underlying) - Conversion
Common Shares
2020-11-02+822,311→ 822,311 total(indirect: See footnote) - Purchase
Common Shares
2020-11-02$15.00/sh+523,833$7,857,495→ 2,579,657 total(indirect: See footnote) - Purchase
Common Shares
2020-11-02$15.00/sh+209,500$3,142,500→ 1,031,811 total(indirect: See footnote) - Award
Series D Preferred Stock
2020-09-25$27.11/sh−73,773$1,999,986→ 73,773 total(indirect: See footnote)→ Common Shares (191,787 underlying) - Conversion
Series C-4 Preferred Stock
2020-11-02−272,533→ 0 total(indirect: See footnote)→ Common Shares (708,504 underlying) - Conversion
Series D Preferred Stock
2020-11-02−73,773→ 0 total(indirect: See footnote)→ Common Shares (191,787 underlying) - Conversion
Series C-2 Preferred Stock
2020-11-02−291,999→ 0 total(indirect: See footnote)→ Common Shares (759,110 underlying)
Footnotes (5)
- [F1]The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date.
- [F2]These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII.
- [F3]These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.
- [F4]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund.
- [F5]This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
Documents
Issuer
Galecto, Inc.
CIK 0001800315
Entity typeother
Related Parties
1- filerCIK 0001609405
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 8:00 PM ET
- Size
- 42.9 KB